

ORIGINAL ARTICLE

Epidemiology of Methicillin-Susceptible *Staphylococcus aureus* in a Neonatology Ward

Yvonne Achermann, MD;^{1,a} Kati Seidl, PhD;^{1,a} Stefan P. Kuster, MD, MSc;¹ Nadja Leimer, MSc;¹ Nina Durisch, MD;¹ Evelyne Ajdler-Schäffler, MD;¹ Stephan Karrer, RN;¹ Gabriela Senn;¹ Anne Holzmann-Bürgel;¹ Aline Wolfensberger, MD;¹ Antonio Leone, MD;² Romaine Arlettaz, MD;² Annelies S. Zinkernagel, MD;^{1,b} Hugo Sax, MD^{1,b}

OBJECTIVE. In-hospital transmission of methicillin-susceptible *Staphylococcus aureus* (MSSA) among neonates remains enigmatic. We describe the epidemiology of MSSA colonization and infection in a 30-bed neonatal ward.

DESIGN. Multimodal outbreak investigation

SETTING. A public 800-bed tertiary care university hospital in Switzerland

METHODS. Investigations in 2012–2013, triggered by a MSSA infection cluster, included prospective MSSA infection surveillance, microbiologic screening of neonates and environment, onsite observations, and a prospective cohort study. MSSA isolates were characterized by pulsed-field gel electrophoresis (PFGE) and selected isolates were examined for multilocus sequence type (MLST) and virulence factors.

RESULTS. Among 726 in 2012, 30 (4.1%) patients suffered from MSSA infections including 8 (1.1%) with bacteremia. Among 655 admissions in 2013, 13 (2.0%) suffered from MSSA infections including 2 (0.3%) with bacteremia. Among 177 neonates screened for *S. aureus* carriage, overall 77 (44%) tested positive. A predominant PFGE-1-ST30 strain was identified in 6 of 30 infected neonates (20%) and 30 of 77 colonized neonates (39%). This persistent clone was *pvl*-negative, *tst*-positive and belonged to *agr* group III. We found no environmental point source. MSSA carriage was associated with central vascular catheter use but not with a particular midwife, nurse, physician, or isolette. Observed healthcare worker behavior may have propagated transmission via hands and fomites. Despite multimodal interventions, clonal transmission and colonization continued and another clone, PFGE-6-ST5, became predominant.

CONCLUSIONS. Hospital-acquired MSSA clones represent a high proportion of MSSA colonization but not MSSA infections in neonate inpatients. In contrast to persisting MSSA, transmission infection rates decreased concurrently with interventions. It remains to be established whether eradication of hospital-acquired MSSA strains would reduce infection rates further.

Infect. Control Hosp. Epidemiol. 2015;36(11):1305–1312

Transmission of *Staphylococcus aureus* in healthcare settings, including among newborns, is frequent.^{1–3} Despite a similar attributable mortality between methicillin-resistant *S. aureus* (MRSA) and methicillin-susceptible *S. aureus* (MSSA),⁴ literature focuses almost exclusively on MRSA.^{1,5} *S. aureus* persistently colonizes ~20%–40% of healthy individuals⁶ and ~5%–55% of infants, including neonates.^{7–10} Several bacterial and host factors play roles in the process of colonization,^{6,11,12} and the risk of infection is 3 to 6 times higher in colonized individuals compared with noncolonized individuals.^{13–15} There are no generally accepted recommendations to

decolonize neonates for MSSA. Furthermore, no solid data exist on overall MSSA infection rates in this population.

A monoclonal cluster of 5 MSSA infections among neonates in our hospital's 30-bed neonatal ward (NNW) in January 2012 triggered an in-depth investigation of *S. aureus* epidemiology during 2012–2013 to elucidate strain clonality, potential reservoirs, and transmission routes in this population. The objective of this report is to add real-world epidemiological data to the recent debate regarding the infectious risk engendered by MSSA colonization in neonates and the consequential need for interventions.

Affiliations: 1. Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland; 2. Division of Neonatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.

^aAuthors with equal contribution.

^bAuthors with equal contribution.

PREVIOUS PRESENTATION: Parts of this study were presented as an oral presentation at the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, USA, September 17–23, 2012.

Received March 18, 2015; accepted June 18, 2015; electronically published August 20, 2015

© 2015 by The Society for Healthcare Epidemiology of America. All rights reserved. 0899-823X/2015/3611-0008. DOI: 10.1017/ice.2015.184

STUDY POPULATION

Setting

The NNW at the University Hospital of Zurich, Switzerland, features 30 beds for neonates including 8 beds for neonatal intensive care and 5 beds for intermediate care. The average nurse-to-patient ratio in 2012 was 1:3 during the day and 1:4 during night shifts.

The hospital's infection surveillance program includes daily reviews of clinical microbiology and virology results targeted on epidemiologically important pathogens, and surgical site infections associated with selected surgical procedures (eg, cardiac surgery, appendectomy, etc.). Annual institution-wide prevalence studies are conducted as well.

Case Definitions

A case was defined as a newborn admitted to the NNW between January 1, 2011, and December 31, 2013, from whom *S. aureus* had been isolated. We distinguished between *S. aureus* colonization and infection. The latter was defined as a positive *S. aureus* culture and clinical signs of infection, with or without bacteremia.

METHODS

Outbreak Investigation

Epidemiological investigation. The outbreak investigation consisted of 3 distinct periods: (1) a retrospective period during 2011 with identification of cases with *S. aureus* infections that occurred based on isolation of *S. aureus* and documented symptoms; (2) a prospective 6-week surveillance screening period from February 20 through April 1, 2012, of all neonates for nasal *S. aureus* carriage at the day of delivery, at the day of ward discharge, and once weekly every Monday; (3) a follow-up period during 2012–2013 with prospective surveillance of *S. aureus* infections detected during regular ward rounds by 3 investigators (YA, ND, EA) and positive microbiological samples. Bacteremia of any etiology was recorded. Colonization was monitored by repeated prevalence screenings of the nares of all neonates at convenient time points.

Additional source investigation. The following additional source investigation activity was conducted: environmental microbiological sampling (isolettes, vital sign monitors, stethoscopes, telephones, computer mice, ultrasound heads, and preparations of enteral feeding solutions); extensive onsite observations including time–motion studies of care activity and standardized hand hygiene observation according to the World Health Organization's "My Five Moments of Hand Hygiene" method;^{16,17} assessment of alcohol-based hand rub consumption; documentation of all cases and controls with demographic and clinical information.

The Zurich Ethics Review Board formally waived the necessity for an ethics evaluation.

Risk Factor Analysis

To assess risk factors for the presence of MSSA and for MSSA carriage, 2 analyses were performed on the prospective 6-week cohort. Differences in means and medians were compared using the Student *t* test and the Wilcoxon rank-sum test, respectively, and differences in group proportions were evaluated using χ^2 or Fisher's exact tests, as appropriate.

Multivariate logistic regression analyses was used to assess risk factors for MSSA carriage. Risk factors with $P < .1$ in univariate analyses were considered for inclusion in multivariate models based on clinical judgment. The limited number of outcomes was factored in when building the models to prevent overfitting. Variables with logically suspected collinearity were excluded from multivariate models. All calculations were performed using Stata software, version 11.2 (Stata Corp, College Station, Texas, USA). $P < .05$ was considered statistically significant.

Microbiology

Sample collection. Samples were obtained from the nares of neonates and from various surfaces using cotton swabs premoistened with sterile saline. In addition, fingers of healthcare workers (HCWs) were swiped directly onto agar plates. Enteral nutrition (Adapta, Prematil) and additives (Frauen Milch supplement and maltodextrin) were collected as liquid samples from ready-to-use milk bottles.

Bacterial identification. Nasal swabs, enteral nutrition, and environmental swabs were plated directly onto Columbia nalidixic acid blood agar and sheep blood agar plates (BioMérieux, Marcy l'Etoile, France) and incubated for 24–48 h at 37°C. For HCW finger sampling, tryptic soy agar plates with neutralizers (Merck, Kenilworth, NJ) were used. Isolates were identified as *S. aureus* by positive catalase and StaphAureux tests (Remel Europe, Dartford, Kent, UK). Oxacillin, cefoxitin, and ampicillin resistance tests were performed using the Kirby-Bauer disc diffusion method.

Pulsed-field gel electrophoresis. The first *S. aureus* isolate detected in a given neonate and all the *S. aureus* isolates from the environment were characterized by pulsed-field gel electrophoresis (PFGE) of total-genome SmaI (New England Biolabs, Ipswich, MA) digests as previously described.¹⁸ The resulting patterns were analyzed by visual inspection, photocopying by Gel Doc XR (Bio-Rad, Rheinland, Switzerland), and by automated analysis using the GelCompar II computer software (Applied Maths, Kortrijk, Belgium) for relatedness evaluation.

agr grouping and detection of *tst* and *pvl* genes. Representative *S. aureus* isolates belonging to PFGE types that occurred at least 3 times were grown in Luria-Bertani broth medium (Difco Laboratories, Detroit, MI) at 37°C until the stationary growth phase. Genomic DNA used as template for polymerase chain reaction (PCR) was extracted using a standard phenol-chloroform procedure.¹⁹ *agr* typing was

performed by multiplex PCR using previously described primers and conditions.²⁰ *S. aureus* strains RN6390, RN6607, Sanger252, and RN8540, corresponding to *agr* functional groups I, II, III, and IV, respectively, were obtained from the Network on Antimicrobial Resistance in *S. aureus* (NARSA) and served as controls. Results from *agr*-PCRs served as positive controls for the integrity of genomic DNA extracts, which were also used for the detection of *tst* and *pvl* genes using previously published methods.^{20,21} *pvl* encodes for Panton-Valentine leukocidin, a pore-forming toxin that targets phagocytic leukocytes, especially polymorph-nuclear leukocytes, which constitute the first line of defense against invading *S. aureus*.²² *tst* encodes for toxic shock syndrome toxin, a *S. aureus* superantigen responsible for toxic shock syndrome. Strains N315 and JE2 (also from NARSA) were used as controls for the specificity of PCR amplifications for *tst* and *pvl*, respectively.

Multilocus Sequence Typing (MLST)

The allelic profiles, referred to as the sequence types of representative strains of a distinct PFGE type that included >2 strains, were defined by the nucleotide sequence of an internal fragment of 7 housekeeping genes (*arcC-aroE-glpF-gmk-pta-tpi-yqiL*), as previously described.²³ MLST allele names and STs were derived using the MLST database (<http://www.mlst.net>).

RESULTS

Retrospective Cases in 2011

Among 697 neonates hospitalized during 2011, 26 cases (3.7%) of MSSA infection occurred (Figure 1A) including 8 (1.2%) with bacteremia. Strains were generally unavailable for typing.

Prospective 6-Week Surveillance Screening Period in 2012

During the 6-week surveillance screening period in early 2012, all 87 admissions were included in this study. Of those, 26 infants were asymptomatic nasal carriers (30%) and 3 had infections (3.5%), including 1 neonate with conjunctivitis, 1 with bronchopneumonia, and 1 with bacteremia secondary to a skin infection. A predominant MSSA strain, PFGE-1-ST30, was found in 11 carriers (42%) but not among infected infants.

Follow-Up Period During 2012–2013

Infections with S. aureus during 2012–2013. In 2012, 726 infants were hospitalized in our NNW; of these, 30 (4.1%) were infected with MSSA, and 8 (1.1%) suffered from bacteremia (Figure 1). Of 30 MSSA infections, 6 (20%) were caused by PFGE-1-ST30, 4 by PFGE-1a-ST30, 2 by PFGE-1b-ST30, 1 by PFGE-3-ST34, 2 by PFGE-6-ST5. The remaining 15 infections were caused by other PFGE types with distinct patterns (Figure 2).

In 2013, the incidence of MSSA infections decreased to 2.0% (13 of 655 admissions; $P=.03$) and the incidence of bacteremia decreased to 0.3% (2 of 655 admissions; $P=.11$). None of the infections were caused by the 2012 MSSA PFGE-1-ST30 predominant strain. Of the 13 MSSA infections, 4 were caused by PFGE-6-ST5 and 2 were caused by PFGE-4-ST109, both of which were already present in 2012 (Figures 1 and 2). In addition, 2 infections (including the bacteremia) were caused by PFGE-2-ST45, which had already caused bacteremia in 2011 (Figures 1 and 2). The remaining infections were caused by isolates with distinct PFGE patterns (Supplementary Figure 2).

In 2012, the incidence of bacteremia caused by any microbial pathogen was 4.7% (34 of 726 admissions). Of these 34 cases, 13 bacteremia cases (38%) were caused by coagulase-negative staphylococci; 8 (24%) by *S. aureus*; 8 (24%) by *Streptococcus* spp.; 3 (9%) by *Bifidobacterium* spp.; 1 (3%) by *Enterococcus* spp.; and 1 (3%) by *Escherichia coli*. No incidents of *Klebsiella pneumoniae*, *Citrobacter* spp., or *Eikenella* spp. were identified in 2012. In 2013, the incidence of bacteremia caused by any microbial pathogen was 3.5% (23 of 655 admissions). Of these 23 cases, 11 (48%) were caused by coagulase-negative staphylococci; 2 (9%) by *S. aureus*; 1 (4%) by *Bifidobacterium* spp.; 1 (4%) by *Enterococcus* spp.; 3 (13%) by *Escherichia coli*; 1 (4%) by *Klebsiella pneumoniae*; 1 (4%) by *Citrobacter* spp.; and 1 (4%) by *Eikenella* spp.

Colonization with S. aureus during 2012 and 2013. In 2012, 150 of all 726 neonate admissions (21%) were screened for *S. aureus* colonization. Of these 150 neonates, 62 (41%) tested positive for MSSA carriage; 27 of these 62 (44%) were identified as the PFGE-1-ST30 strain. Ten point-prevalence screening studies during 2012 resulted in a median MSSA carriage of 52% (range, 24%–75%). Of these, 17%–92% were identified as PFGE-1-ST30 strains (Figure 1B). Colonization with PFGE-1-ST30 was persistently found in prevalence screenings. PFGE-1-ST30 is *pvl*-negative, *tst*-positive, and belongs to *agr* group III. The 2 related PFGE types 1a and 1b differed by 1 and 2 bands, respectively, and also belonged to the ST30 strain. Another clustered strain also differed from PFGE-1-ST30 in 1 band and was typed as PFGE-3-ST34 (Figure 2). Supplementary Figure 1 displays the remaining PFGE strain patterns during 2012.

In 2013, in a single prevalence screening during week 42, we found 15 MSSA carriers among 27 screened neonates (56%), of whom 3 (11%) were colonized with PFGE-1-ST30 and 8 (57%) were colonized with PFGE-6-ST5 (Figure 1B). PFGE-1-ST30 also caused 3 infections in the first half of 2013 (Figure 1A).

None of the *S. aureus* strains was methicillin resistant.

Source Investigation

Repeated time-motion studies revealed non-conforming HCW behavior that could explain hand transmission of *S. aureus* directly or via fomites, eg, touching monitors or incubator doors of consecutive patients without intermittent hand cleansing. HCWs frequently used portable phones,




FIGURE 1. Epidemiology of *Staphylococcus aureus* infection and colonization, 2011–2013. MSSA, methicillin-suseptible *Staphylococcus aureus*; 1, strain PFGE-1-ST30; 1a, strain PFGE-1a-ST30; 1b, strain PFGE-1b-ST30; 2, strain PFGE-2-ST45; 3, strain PFGE-3-ST34; 4, strain PFGE-4-ST109; 6, strain PFGE-6-ST5. (A) Incidence of *Staphylococcus aureus* infections among all neonates (B) Prevalence assessments of *Staphylococcus aureus* colonization and preventive measures

calculators, computers, or incubators in sequence without hand hygiene. During our observations in the unit, we could not single out a particular HCW with extremely low hand

hygiene compliance or obvious skin disease who appeared to be a potential super-spreader. Isolettes were cleaned according to protocol based on probing observations.




FIGURE 2. Selected clustered *Staphylococcus aureus* genotype patterns.

Staphylococcus aureus multilocus sequence typing (MLST) of the outbreak strain with pulsed-field gel electrophoresis (PFGE) identification number 1, its 3 variants (1a, 1b, and 3) with similar PFGE patterns and other clones that occurred at least 3 times between January 2011 to December 2013 in the neonatal ward. For each clone, 1 representative isolate is shown. ID, strain identification; Year*, year in which the respective clone was detected; PFGE ID, PFGE identification; agr, pvl, tst, virulence factors; ST, sequence type.

Overall, we performed 43 environmental swabs, of which 3 swabs (7%) were positive for MSSA. Of these 3 swabs, 2 were positive for PFGE-1-ST30: 1 on a bedside monitor and 1 on an isolette door handle of a colonized neonate with the same strain. The third MSSA-positive swab was a unique strain found on a computer mouse in an office space. No *S. aureus* grew from delivery facilities or milk preparations.

From 3 of 13 conveniently tested HCWs, MSSA was isolated from fingers before hand cleansing and from the fingers of 1 HCW after hand cleansing. None of these MSSA strains were PFGE-1-ST30 or any other clustered strain.

Risk Factor Analysis

Of the 87 neonate patients in the prospective 6-week cohort, 29 carried any MSSA and 11 carried the predominant PFGE-1-ST-30 strain. MSSA acquisition was independently associated with vascular catheterization (Table 1) but not with any particular midwife, nurse, or physician. Statistical power was too limited to detect differences between MSSA acquisition in general and acquisition of PFGE-1-ST-30.

Control Measures

Control measures were sequentially reinforced as the persistence of clonally related MSSA strains became clear (Figure 2). All HCWs were repeatedly informed about the outbreak and its most likely transmission pathways. Each bed was newly equipped with alcohol-based hand rub dispensers, and portable 100-mL containers were introduced. Training sessions were held based on the “Five Moments of Hand Hygiene” concept in fall 2012. Overall performance was 66% (162 of 245) before and 73% (148 of 202) after training sessions (adjusted odds ratio, 1.18; 95% confidence interval, 0.77–1.82, multivariate logistic regression controlling for professional category and indications).¹⁷ Hand rub consumption increased 19% from 189 L per 1,000 patient days in 2012 to 224 L in 2013 ($P < .001$). Cleaning and disinfection schedules were intensified and well applied according to audits. The NNW was never closed for admissions,

and no contact isolation or cohorting was introduced. On September 5, 2012, the entire NNW moved to a newly constructed and equipped location in the hospital.

DISCUSSION

A cluster of 5 *S. aureus* infections in neonates triggered an outbreak investigation including extensive screening of asymptomatic carriers. We identified a predominant MSSA clone PFGE-1-ST30. This clone persisted and accounted for 20% of the MSSA infections and 39% of all nasal swabs growing MSSA. In 2013, a new clone, PFGE-6-ST5, became predominant. Other minor clusters occurred and were also responsible for infections. Intensified infection control efforts and moving the unit to a new location did not stop *S. aureus* transmission but infection incidence did decrease, in 2013. We inferred that, once introduced by HCWs or parents, PFGE-1-ST30 and other clonal MSSA strains were propagated among neonates through direct and indirect hand transmission, which is a notoriously efficient pathway in neonatology.²⁴

Although vertical transmission from mothers to neonates occurs habitually,²⁵ this does not explain the striking clonality. *S. aureus* has been shown to survive for up to 8 weeks on inanimate surfaces.^{26–28} We detected PFGE-1-ST30 on a monitor and an incubator door of a neonate colonized with the same strain, but these surfaces were unlikely sustained point sources because they are cleaned repeatedly. Furthermore, and very importantly, persistence of clones beyond moving to an entirely new facility makes a persistent environmental point source unlikely.

Colonized HCWs have been responsible for *S. aureus* outbreaks in neonates.^{2,29,30} We found hands of 3 HCWs to be positive for MSSA, providing proof for at least transient MSSA hand carriage. Without systematic HCW screening, we cannot formally exclude the possibility that a colonized HCW acted as a point source. However, it is unlikely that 1 person colonized so many infants. The case control studies did, however, exclude the existence of a source individual on the obstetric team.

TABLE 1. Prospective Cohort of 87 Neonates with Surveillance Screening for Nasal *Staphylococcus aureus* Carriage at the Day of Delivery, of Discharge from the Ward, and Once Weekly Every Monday from February 20 Through April 1, 2012TABLE 1A. Risk Factors for Colonization with Methicillin-Susceptible *Staphylococcus aureus* (Univariate and Multivariate Analyses)

Characteristics	Colonized with MSSA N = 29	Not Colonized with MSSA N = 58	Unadjusted Odds Ratio (95% CI)	P Value	Adjusted Odds Ratio (95% CI)	P Value
Female sex, No. (%)	10 (35)	30 (52)	0.5 (0.2–1.2)	.13		
Gestation age, wk, median (range)	34 (27–41)	36 (25–42)		.002		
Gestation age <33 weeks, No. (%)	12 (41)	7 (12)	5.1 (1.7–15.2)	.005		
Birth weight, g, median (range)	1,920 (570–3,940)	2,465 (840–4,130)		.004		
Birth weight <1,500 g, No. (%)	8 (28)	2 (4)	10.7 (2.1–54.4)	.002	2.6 (0.4–16.8)	.32
Length of stay, d, median (range)	14 (3–74)	6 (0–35)		<.001		
Length of stay >14 d	14 (48)	7 (12)	6.8 (2.3–19.9)	<.001	2.8 (0.8–10.4)	.12
Stay in incubator, No. (%)	19 (66)	25 (43)	2.5 (1.0–6.3)	.07		
Stay in incubator, d, median (range)	6 (0–40)	0 (0–10)		.001		
Stay in incubator >5 d, No. (%)	15 (52)	11 (19)	4.6 (1.7–12.2)	.003		
Stay in neonatal intensive care unit, n (%)	18 (62)	12 (21)	6.3 (2.3–16.8)	<.001		
Cesarian delivery, No. (%)	24 (83)	39 (67)	2.3 (0.7–7.1)	.20		
Parenteral nutrition, No. (%)	17 (59)	15 (26)	4.1 (1.6–10.4)	.004		
Surgical intervention, No. (%)	1 (3)	1 (2)	2.0 (0.1–33.8)	1.00		
Any vascular catheter, No. (%)	23 (79)	20 (34)	7.3 (2.6–20.8)	<.001	4.4 (1.4–13.6)	.011
Central venous catheter, No. (%)	5 (17)	2 (3)	5.8 (1.1–32.2)	.039		
Umbilical arterial catheter, No. (%)	14 (48)	7 (12)	6.8 (2.3–19.9)	<.001		
Peripheral venous catheter, No. (%)	23 (79)	19 (33)	7.9 (2.7–22.5)	<.001		

NOTE. MSSA, methicillin-susceptible *S. aureus*; CI, confidence intervalTABLE 1B. Risk Factors for Colonization with a PFGE-1-ST30 *Staphylococcus aureus* Strain (Univariate Analysis)

Characteristics	Colonized with PFGE 1-ST30 N = 11	Not Colonized or Colonized with Other Sequence Type MSSA N = 76	Unadjusted Odds Ratio (95% CI)	P value
Female sex, No. (%)	4 (36)	36 (47)	0.6 (0.2–2.3)	.54
Gestation age, wk, median (range)	31 (26–37)	36 (24–41)		<.001
Gestation age <33 wk, No. (%)	6 (55)	13 (17)	5.8 (1.5–22.0)	.012
Birth weight, g, median (range)	1,550 (570–3,330)	2,375 (840–4,130)		.004
Birth weight <1,500 g, No. (%)	5 (45)	5 (7)	11.8 (2.7–52.7)	.002
Length of stay, d, median (range)	21 (4–74)	7 (0–52)		.002
Length of stay >14 d	8 (73)	13 (17)	12.9 (3.0–55.4)	<.001
Stay in neonatal intensive care unit, No. (%)	8 (73)	22 (29)	6.5 (1.6–27.0)	.007
Cesarian delivery, No. (%)	11 (100)	52 (68)	NA	.03
Parenteral nutrition, No. (%)	7 (64)	25 (33)	3.6 (1.0–13.3)	.09
Any vascular catheter, No. (%)	8 (73)	35 (46)	3.1 (0.8–12.7)	.12

NOTE: PFGE, pulsed-field gel electrophoresis; MSSA, methicillin-susceptible *S. aureus*; CI, confidence interval.

In our 2 case-control studies, we found birth weight, prolonged length of stay, and use of vascular catheters to be independent risk factors for MSSA acquisition in general as well as specifically for PFGE-1-ST30 acquisition. Graham et al² described a similar correlation of colonization/infection with length of hospital stay.

Many effective outbreak control strategies have been described in the literature including cohorting of neonates and

HCW, strong leadership, staff training in proper hand hygiene, readily accessible alcohol-based hand sanitizer at the point of care, decolonization with mupirocin,^{31,32} and closing the ward for in-depth cleaning. A recent study documented reduction of MSSA colonization and infection by unselective use of mupirocin.³³ However, mupirocin use harbors the risk of resistance³⁴ and possible future treatment failure. Thus, we focused our control efforts on standard infection control

measures including promoting hand hygiene through training and ergonomic dispenser placement (Figure 1B).³⁵ While formally observed hand hygiene performance did not significantly improve with behavioral interventions, hand rub consumption increased and HCW problem awareness (measured anecdotally) did improve. Moving the NNW to a new location was thought to act as behavior modifier and to eliminate any potential environmental source. While these strategies failed to control clonal MSSA transmission between babies, overall MSSA infection incidence decreased in 2013.

The main *S. aureus* strain was identified as PVL-negative ST30 MSSA. ST30 is a very common genotype that can both colonize and cause disease in inpatients and in the community.³⁶ Even though ST30 is circulating in Europe, it is not a predominant genotype among MRSA or MSSA strains.^{37,38}

Data on MSSA colonization rates and clonality in the neonatal population are rare. A pediatric study showed that by 100 hours of hospitalization, 43% of newborns of *S. aureus*-colonized mothers were also colonized in contrast to 7% of the newborns of *S. aureus*-negative mothers.²⁵ HCWs and the environment are likely sources for neonatal *S. aureus* colonization.^{2,29,30} Hence, it is difficult to fully appraise the present findings. In very young infants, colonization with *S. aureus* of up to 40%, a level equal to our findings, seems to be physiological in the community.³⁹ A prevalence study in Swiss babies <2 months of age, excluding neonates, examined the prevalence within 2 days of hospital stay and found 42% MSSA carriers.³⁹ Acquisition is probably facilitated by the inexperienced immune system. While *S. aureus* demonstrated high genetic variability in the community,³⁹ the clonality in our investigation proves healthcare-associated transmission.

Even improving standard infection prevention measures to a level that met or exceeded that of other NNWs did not seem to prevent transmission. Consequently, clonal spread of MSSA may occur in many NNWs around the world unnoticed, rendering MSSA transmission an endemic situation rather than an outbreak. In a recent account of *S. aureus* epidemiology among neonates, 39% (54 of 139) of included infants were affected by *S. aureus*, the large majority of strains being methicillin susceptible.⁴⁰ In this study, *S. aureus* infection incidence was 12.2% (compared with our incidence rates of 4.1% in 2012 and 2.0% in 2013). Of 6 cases in a MSSA infection cluster, 5 showed the same PFGE type, but typing of colonizing strains was not performed. A potential point source concerned white protection gowns, while hand hygiene compliance was 60% and 76% in two NNW sectors.

From these study results, an important question arises regarding whether clonality leads to an increased burden of MSSA infections directly through the virulence of predominant strains or indirectly via increased colonization rates. Without prolonged prospective surveillance of colonization and infection incidence, this question cannot be answered with certainty. However, in our investigation, clonal strains were less frequent in MSSA-infected neonates than in MSSA-colonized neonates. PFGE-1-ST-30 was particularly successful in spreading but less in generating infections.

CONCLUSION

With this report, we add insights into the hitherto scarcely known epidemiology of methicillin-susceptible *S. aureus* in a neonatal inpatient population. We found sustained healthcare-associated clonal MSSA transmission resulting in colonization more often than infection. Based on strain typing, observations, environmental specimens, and analysis of risk factors, direct and indirect spread via HCW hands constituted the most likely explanation. Clonal spread did not cease with multimodal control measures, but MSSA infection incidence decreased. Whether eradication of the clonal MSSA strains would lead to reduced infection rates remains an open question.

ACKNOWLEDGMENTS

Financial support: This work was supported by the Swiss National Foundation (Grant no. 310030_146295/1 to ASZ).

Potential conflicts of interest: All authors report no conflicts of interest relevant to this article.

Address correspondence to Hugo Sax, MD, University Hospital of Zurich, University of Zurich, Division of Infectious Diseases and Hospital Epidemiology, Raemistrasse 100, CH-8091 Zurich, Switzerland (hugo.sax@usz.ch).

SUPPLEMENTARY MATERIAL

To view supplementary material for this article, please visit <http://dx.doi.org/10.1017/ice.2015.184>

REFERENCES

1. Sax H, Posfay-Barbe K, Harbarth S, et al. Control of a cluster of community-associated, methicillin-resistant *Staphylococcus aureus* in neonatology. *J Hosp Infect* 2006;63:93–100.
2. Graham PL 3rd, Morel AS, Zhou J, et al. Epidemiology of methicillin-susceptible *Staphylococcus aureus* in the neonatal intensive care unit. *Infect Control Hosp Epidemiol* 2002;23:677–682.
3. Carey AJ, Duchon J, Della-Latta P, Saiman L. The epidemiology of methicillin-susceptible and methicillin-resistant *Staphylococcus aureus* in a neonatal intensive care unit, 2000–2007. *J Perinatol* 2010;30:135–139.
4. Wang JL, Chen SY, Wang JT, et al. Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant *Staphylococcus aureus* and methicillin-susceptible *S. aureus*. *Clin Infect Dis* 2008;46:799–806.
5. Giuffrè M, Cipolla D, Bonura C, et al. Epidemic spread of ST1-MRSA-IVa in a neonatal intensive care unit, Italy. *BMC Pediatr* 2012;12:64.
6. Weidenmaier C, Goerke C, Wolz C. *Staphylococcus aureus* determinants for nasal colonization. *Trends Microbiol* 2012;20:243–250.
7. Rana D, Abughali N, Kumar D, Super DM, Jacobs MR, Kumar ML. *Staphylococcus aureus*, including community-acquired methicillin-resistant *S. aureus*, in a level III NICU: 2001 to 2008. *Am J Perinatol* 2012;29:401–408.
8. Datta F, Erb T, Heininger U, et al. A multicenter, cross-sectional study on the prevalence and risk factors for nasal colonization with *Staphylococcus aureus* in patients admitted to children's hospitals in Switzerland. *Clin Infect Dis* 2008;47:923–926.

9. Jimenez-Truque N, Tedeschi S, Saye EJ, et al. Relationship between maternal and neonatal *Staphylococcus aureus* colonization. *Pediatrics* 2012;129:e1252–e1259.
10. Pinter DM, Mandel J, Hulten KG, Minkoff H, Tosi MF. Maternal-infant perinatal transmission of methicillin-resistant and methicillin-sensitive *Staphylococcus aureus*. *Am J Perinatol* 2009;26:145–151.
11. Frank DN, Feazel LM, Bessesen MT, Price CS, Janoff EN, Pace NR. The human nasal microbiota and *Staphylococcus aureus* carriage. *PLoS One* 2010;5:e10598.
12. Ruimy R, Angebault C, Djossou F, et al. Are host genetics the predominant determinant of persistent nasal *Staphylococcus aureus* carriage in humans? *J Infect Dis* 2010;202:924–934.
13. Cope A, Shooter RA, Green SM, Noble WC. Nasal carriage of *Staphylococcus aureus* by newborn babies. *Br Med J* 1961;2:329–330.
14. Von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of *Staphylococcus aureus* bacteraemia. Study Group. *N Engl J Med* 2001;344:11–16.
15. Wertheim HF, Vos MC, Ott A, et al. Risk and outcome of nosocomial *Staphylococcus aureus* bacteraemia in nasal carriers versus non-carriers. *Lancet* 2004;364:703–705.
16. Sax H, Allegranzi B, Chraïti MN, Boyce J, Larson E, Pittet D. The World Health Organization hand hygiene observation method. *Am J Infect Control* 2009;37:827–834.
17. Sax H, Allegranzi B, Uckay I, Larson E, Boyce J, Pittet D. ‘My five moments for hand hygiene’: a user-centred design approach to understand, train, monitor and report hand hygiene. *J Hosp Infect* 2007;67:9–21.
18. Chung M, de LH, Matthews P, et al. Molecular typing of methicillin-resistant *Staphylococcus aureus* by pulsed-field gel electrophoresis: comparison of results obtained in a multi-laboratory effort using identical protocols and MRSA strains. *Microb Drug Resist* 2000;6:189–198.
19. Barnett R, Larson G. A phenol-chloroform protocol for extracting DNA from ancient samples. *Methods Mol Biol* 2012;840:13–19.
20. Jarraud S, Mougél C, Thioulouse J, et al. Relationships between *Staphylococcus aureus* genetic background, virulence factors, agr groups (alleles), and human disease. *Infect Immun* 2002;70:631–641.
21. Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing *Staphylococcus aureus* in primary skin infections and pneumonia. *Clin Infect Dis* 1999;29:1128–1132.
22. Labandeira-Rey M, Couzon F, Boisset S, et al. *Staphylococcus aureus* Panton-Valentine leukocidin causes necrotizing pneumonia. *Science* 2007;315:1130–1133.
23. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of *Staphylococcus aureus*. *J Clin Microbiol* 2000;38:1008–1015.
24. Oelberg DG, Joyner SE, Jiang X, Laborde D, Islam MP, Pickering LK. Detection of pathogen transmission in neonatal nurseries using DNA markers as surrogate indicators. *Pediatrics* 2000;105:311–315.
25. Leshem E, Maayan-Metzger A, Rahav G, et al. Transmission of *Staphylococcus aureus* from mothers to newborns. *Pediatr Infect Dis J* 2012;31:360–363.
26. Beard-Pegler MA, Stubbs E, Vickery AM. Observations on the resistance to drying of staphylococcal strains. *J Med Microbiol* 1988;26:251–255.
27. Desai R, Pannaraj PS, Agopian J, Sugar CA, Liu GY, Miller LG. Survival and transmission of community-associated methicillin-resistant *Staphylococcus aureus* from fomites. *Am J Infect Control* 2011;39:219–225.
28. Conceicao T, Aires de Sousa M, Miragaia M, et al. *Staphylococcus aureus* reservoirs and transmission routes in a Portuguese Neonatal Intensive Care Unit: a 30-month surveillance study. *Microb Drug Resist* 2012;18:116–124.
29. Bertin ML, Vinski J, Schmitt S, et al. Outbreak of methicillin-resistant *Staphylococcus aureus* colonization and infection in a neonatal intensive care unit epidemiologically linked to a healthcare worker with chronic otitis. *Infect Control Hosp Epidemiol* 2006;27:581–585.
30. Gomez-Gonzalez C, Alba C, Otero JR, Sanz F, Chaves F. Long persistence of methicillin-susceptible strains of *Staphylococcus aureus* causing sepsis in a neonatal intensive care unit. *J Clin Microbiol* 2007;45:2301–2304.
31. Kim YH, Chang SS, Kim YS, et al. Clinical outcomes in methicillin-resistant *Staphylococcus aureus*-colonized neonates in the neonatal intensive care unit. *Neonatology* 2007;91:241–247.
32. Lepelletier D, Corvec S, Caillon J, Reynaud A, Roze JC, Gras-Leguen C. Eradication of methicillin-resistant *Staphylococcus aureus* in a neonatal intensive care unit: which measures for which success? *Am J Infect Control* 2009;37:195–200.
33. Delaney HM, Wang E, Melish M. Comprehensive strategy including prophylactic mupirocin to reduce *Staphylococcus aureus* colonization and infection in high-risk neonates. *J Perinatol* 2013;33:313–318.
34. Lepointeur M, Royer G, Bourrel AS, et al. Prevalence of resistance to antiseptics and mupirocin among invasive coagulase-negative staphylococci from very preterm neonates in NICU: the creeping threat? *J Hosp Infect* 2013;83:333–336.
35. Allegranzi B, Pittet D. Role of hand hygiene in healthcare-associated infection prevention. *J Hosp Infect* 2009;73:305–315.
36. Robinson DA, Kearns AM, Holmes A, et al. Re-emergence of early pandemic *Staphylococcus aureus* as a community-acquired methicillin-resistant clone. *Lancet* 2005;365:1256–1258.
37. Grundmann H, Aanensen DM, van den Wijngaard CC, Spratt BG, Harmsen D, Friedrich AW. Geographic distribution of *Staphylococcus aureus* causing invasive infections in Europe: a molecular-epidemiological analysis. *PLoS Med* 2010;7:e1000215.
38. Rolo J, Miragaia M, Turlej-Rogacka A, et al. High genetic diversity among community-associated *Staphylococcus aureus* in Europe: results from a multicenter study. *PLoS One* 2012;7:e34768.
39. Megevand C, Gervais A, Heininger U, et al. Molecular epidemiology of the nasal colonization by methicillin-susceptible *Staphylococcus aureus* in Swiss children. *Clin Microbiol Infect* 2010;16:1414–1420.
40. Romano-Bertrand S, Filleron A, Mesnage R, et al. *Staphylococcus aureus* in a neonatal care center: methicillin-susceptible strains should be a main concern. *Antimicrob Resist Infect Control* 2014;3:21.